Drug intelligence / Profile preview

gentamicin + metronidazole + rifaximin

Development stage: Preclinical
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

A combination antibiotic regimen consisting of gentamicin, metronidazole, and rifaximin. This three-drug combination has been used for treating refractory Crohn's disease, pyoderma gangrenosum, small intestinal bacterial overgrowth, and resistant Clostridium difficile infections. The combination leverages the complementary antimicrobial properties of each component: gentamicin (an aminoglycoside targeting Gram-negative bacteria), metronidazole (effective against anaerobes), and rifaximin (a non-systemic antibiotic that inhibits bacterial RNA synthesis).

Targets

rpoB (DNA-directed RNA polymerase subunit beta)Bacterial Ribosome

Beyond the preview

Go deeper on gentamicin + metronidazole + rifaximin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gentamicin + metronidazole + rifaximin.

Explore the full profile